UBS raised the firm’s price target on Guardant Health (GH) to $70 from $65 and keeps a Buy rating on the shares. Guardant Health reported a quarterly beat, with guidance raised amid better volume and average selling price, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $65 from $60 at BTIG
- Guardant Health price target raised to $65 from $60 at Canaccord
- Guardant Health’s Strong Growth Potential and Upward Trajectory Justifies Buy Rating
- Guardant Health: Strong Financial Performance and Growth Potential Justify Buy Rating
- Guardant Health: Strong Financial Performance and Strategic Positioning Drive Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue